Shristi Upadhyay Banskota1, Nabin Khanal2, Vijaya Raj Bhatt3,4. 1. Department of Internal Medicine, Cook County Health, Chicago, Illinois. 2. Franciscan Physician Network Oncology & Hematology Specialists, St Francis hospital, Indianapolis, Indiana. 3. Division of Hematology-Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska. 4. Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Abstract
PURPOSE OF REVIEW: Therapy selection in older adults with acute myeloid leukemia (AML) can be challenging because of a higher incidence of high-risk cytogenetic and molecular features conferring chemoresistance and poor functional status leading to increased treatment-related toxicities. The purpose of this review is to highlight the recent advances in precision medicine in AML that have shown promise to improve outcomes of older adults. RECENT FINDINGS: The utilization of next generation sequencing to identify and target actionable mutations can influence therapy selection in one-third of patients and can result in higher response rates as well as survival compared with those who do not receive targeted therapy. Oral targeted agents are available for AML with IDH 1, IDH2, or FLT3 mutations. Low-intensity venetoclax-based regimens have shown high rates of responses in AML, particularly among those with NPM1 and IDH2 mutations; responses are often durable and associated with minimal residual disease (MRD) negativity. Multiple studies have demonstrated the prognostic significance of flow cytometric MRD, with potential implications for subsequent therapy. SUMMARY: Novel approaches for AML risk-stratification, MRD assessment, and a precision medicine approach offer significant promise to improve survival and quality of life of older adults.
PURPOSE OF REVIEW: Therapy selection in older adults with acute myeloid leukemia (AML) can be challenging because of a higher incidence of high-risk cytogenetic and molecular features conferring chemoresistance and poor functional status leading to increased treatment-related toxicities. The purpose of this review is to highlight the recent advances in precision medicine in AML that have shown promise to improve outcomes of older adults. RECENT FINDINGS: The utilization of next generation sequencing to identify and target actionable mutations can influence therapy selection in one-third of patients and can result in higher response rates as well as survival compared with those who do not receive targeted therapy. Oral targeted agents are available for AML with IDH 1, IDH2, or FLT3 mutations. Low-intensity venetoclax-based regimens have shown high rates of responses in AML, particularly among those with NPM1 and IDH2 mutations; responses are often durable and associated with minimal residual disease (MRD) negativity. Multiple studies have demonstrated the prognostic significance of flow cytometric MRD, with potential implications for subsequent therapy. SUMMARY: Novel approaches for AML risk-stratification, MRD assessment, and a precision medicine approach offer significant promise to improve survival and quality of life of older adults.
Authors: P Boddu; J Jorgensen; H Kantarjian; G Borthakur; T Kadia; N Daver; Y Alvarado; N Pemmaraju; P Bose; K Naqvi; M Yilmaz; S Pierce; M Brandt; C D DiNardo; E J Jabbour; M Konopleva; G Garcia-Manero; J Cortes; F Ravandi Journal: Leukemia Date: 2017-09-18 Impact factor: 11.528
Authors: Uwe Platzbecker; Jan Moritz Middeke; Katja Sockel; Regina Herbst; Dominik Wolf; Claudia D Baldus; Uta Oelschlägel; Anke Mütherig; Lars Fransecky; Richard Noppeney; Gesine Bug; Katharina S Götze; Alwin Krämer; Tilmann Bochtler; Matthias Stelljes; Christoph Groth; Antje Schubert; Marika Mende; Friedrich Stölzel; Christine Borkmann; Anne Sophie Kubasch; Malte von Bonin; Hubert Serve; Mathias Hänel; Ulrich Dührsen; Johannes Schetelig; Christoph Röllig; Michael Kramer; Gerhard Ehninger; Martin Bornhäuser; Christian Thiede Journal: Lancet Oncol Date: 2018-11-12 Impact factor: 41.316
Authors: Monique Terwijn; Wim L J van Putten; Angèle Kelder; Vincent H J van der Velden; Rik A Brooimans; Thomas Pabst; Johan Maertens; Nancy Boeckx; Georgine E de Greef; Peter J M Valk; Frank W M B Preijers; Peter C Huijgens; Angelika M Dräger; Urs Schanz; Mojca Jongen-Lavrecic; Bart J Biemond; Jakob R Passweg; Michel van Gelder; Pierre Wijermans; Carlos Graux; Mario Bargetzi; Marie-Cecile Legdeur; Jurgen Kuball; Okke de Weerdt; Yves Chalandon; Urs Hess; Leo F Verdonck; Jan W Gratama; Yvonne J M Oussoren; Willemijn J Scholten; Jennita Slomp; Alexander N Snel; Marie-Christiane Vekemans; Bob Löwenberg; Gert J Ossenkoppele; Gerrit J Schuurhuis Journal: J Clin Oncol Date: 2013-09-23 Impact factor: 44.544
Authors: Adam Ivey; Robert K Hills; Michael A Simpson; Jelena V Jovanovic; Amanda Gilkes; Angela Grech; Yashma Patel; Neesa Bhudia; Hassan Farah; Joanne Mason; Kerry Wall; Susanna Akiki; Michael Griffiths; Ellen Solomon; Frank McCaughan; David C Linch; Rosemary E Gale; Paresh Vyas; Sylvie D Freeman; Nigel Russell; Alan K Burnett; David Grimwade Journal: N Engl J Med Date: 2016-01-20 Impact factor: 91.245
Authors: Andrew H Wei; Stephen A Strickland; Jing-Zhou Hou; Walter Fiedler; Tara L Lin; Roland B Walter; Anoop Enjeti; Ing Soo Tiong; Michael Savona; Sangmin Lee; Brenda Chyla; Relja Popovic; Ahmed Hamed Salem; Suresh Agarwal; Tu Xu; Kaffa M Fakouhi; Rod Humerickhouse; Wan-Jen Hong; John Hayslip; Gail J Roboz Journal: J Clin Oncol Date: 2019-03-20 Impact factor: 44.544
Authors: Victoria V Prassek; Maja Rothenberg-Thurley; Maria C Sauerland; Tobias Herold; Hanna Janke; Bianka Ksienzyk; Nikola P Konstandin; Dennis Goerlich; Utz Krug; Andreas Faldum; Wolfgang E Berdel; Bernhard Wörmann; Jan Braess; Stephanie Schneider; Marion Subklewe; Stefan K Bohlander; Wolfgang Hiddemann; Karsten Spiekermann; Klaus H Metzeler Journal: Haematologica Date: 2018-06-14 Impact factor: 9.941